The Long Run with Luke Timmerman

Ep204: Troy Wilson on Precision Cancer Drugs and Combos

The Long Run with Luke Timmerman

Show Notes

Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.

More from The Long Run with Luke Timmerman

Oct 7, 2026

Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.

Sep 23, 2026

Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.

Sep 9, 2026

Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.

Aug 25, 2026

Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.

Aug 11, 2026

Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.

See all episodes →